Table 1.
Summary of Patient Clinical Data, Stratified by Lung Function
| Characteristic | Severe | Moderate | Mild | Normal | P |
|---|---|---|---|---|---|
| n | 14 | 25 | 15 | 23 | |
| ppFEV1, median (range) | 32.9 (19.7–39.2) |
46.5 (40.8–59.6) |
74.9 (61.6–79.8) |
101.2 (80.4–119.5) |
|
| Age, y, median (range) | 31.5 (21–61) |
32 (10–63) |
24 (17–51) |
20 (9–66) |
.007 |
| Male, No. | 6 | 11 | 7 | 11 | |
| CFTR genotype, No. | |||||
| Homo-dF508 | 5 | 12 | 7 | 13 | |
| Hetero-dF508 | 9 | 10 | 8 | 10 | |
| Other/other | 0 | 0 | 3 | 0 | |
| BMI, median (range) | 19.43 (16.27–25.69) |
20.73 (16.70–29.81) |
22.23 (19.38–26.07) |
21.51 (16.65–33.91) |
.094 |
| CF-related diabetes, No. (%) | 11 (78.6) |
14 (56.0) |
8 (53.3) |
6 (26.1) |
.015 |
| HbA1c, median (range) | 6.25 (5.3–11.9) |
5.9a (4.9–8.4) |
5.7 (5.0–7.6) |
5.5 (5.1–7.1) |
.009 |
| Clinical microbiology | |||||
| PA, No. (%) | 10 (71.4) | 20 (80.0) | 10 (66.7) | 5 (21.7) | <1.1e-4 |
| SA, No. (%) | 8 (57.1) | 12 (48.0) | 10 (66.7) | 16 (69.6) | .454 |
| MRSA, No. (%) | 4 (28.6) | 6 (24.0) | 6 (40.0) | 4 (17.4) | .486 |
| Burkholderia, No. (%) | 0 (0.0) | 1 (4.0) | 1 (6.7) | 0 (0.0) | .553 |
| Achromobacter, No. (%) | 3 (21.4) | 1 (4.0) | 0 (0.0) | 2 (8.7) | .147 |
| Stenotrophomonas, No. (%) | 0 (0.0) | 1 (4.0) | 3 (20.0) | 2 (8.7) | .191 |
| 16S metadata | |||||
| % Pathogen | 0.857 | 0.589 | 0.532 | 0.195 | 9.05e-5 |
| % Nonpathogen | 0.135 | 0.404 | 0.597 | 0.783 | 3.01e-5 |
Lung function classes are defined as: normal, ppFEV1 > 80; mild, 60 < ppFEV1 ≤ 80; moderate, 40 < ppFEV1 ≤ 60; and severe, ppFEV1 < 40.
Significant differences between lung function categories tested by ANOVA, P -values shown.
Abbreviations: BMI, body mass index; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; HbA1c, hemoglobin A1c; MRSA, methicillin-resistant Staphylococcus aureus. PA, Pseudomonas aeruginosa; SA, Staphylococcus aureus
aTwo patients did not have reported HbA1c values.